|Articles|March 1, 2010

Patient-centred research provides a better understanding of the impact of bottle modifications on glaucoma patients

Sponsored Feature. Xalatan® is to become available across Europe in a newly designed bottle. So what does that mean and what lies behind that decision?

Don’t miss out—get OT Europe updates delivered straight to your inbox.

Latest CME

Video

Precision Vision: Integrating Mechanistic Insight and Clinical Strategy in ADC-Associated Ocular Toxicity

Neel Pasricha, MD; Asim V. Farooq, MD; Susana Campos, MD, MPH

Video

Treatment Optimization in the Evolving Anti-VEGF Era

Carl Danzig, MD, FASRS; Sruthi Arepalli, MD; Priya Vakharia, MD, FASRS

Video

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - Florida

Carl J. Danzig, MD, FASRS

Patient-centred research provides a better understanding of the impact of bottle modifications on glaucoma patients

Latest CME

Precision Vision: Integrating Mechanistic Insight and Clinical Strategy in ADC-Associated Ocular Toxicity

Treatment Optimization in the Evolving Anti-VEGF Era

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - Florida

Trending on Eye Care Network - Ophthalmology Times

Retinal imaging as a window into atrial fibrillation

OCT-980 receives FDA orphan drug designation for retinitis pigmentosa

First patient dosed in phase 3 NPI-001 trial for Usher syndrome RP

The Wills Retina Report: Mapping gene therapy for wet AMD with Carl D. Regillo, MD, and Allen C. Ho, MD

Johnson & Johnson spotlights contrast data, 1 million TECNIS implants, and SmartLOAD delivery